NCT04083495 2025-09-22CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaUNC Lineberger Comprehensive Cancer CenterPhase 2 Recruiting20 enrolled
NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts
NCT02168140 2024-02-13CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaWake Forest University Health SciencesPhase 1 Completed16 enrolled
NCT01644253 2021-05-20Phase 1b Safety and Efficacy Study of TRU-016Aptevo TherapeuticsPhase 1 Terminated87 enrolled
NCT01110135 2017-05-24Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaUniversity of WashingtonPhase 2 Completed43 enrolled 5 charts